MEDTRONIC INTERNATIONAL TRADING SARL

Their core work

Medtronic International Trading is the Swiss-based international trading arm of Medtronic, one of the world's largest medical device companies. Within H2020, they contribute real-world clinical data, device expertise (particularly continuous glucose monitors), and patient outcome measurement infrastructure to large-scale health research consortia. Their role centers on bridging medical device data with clinical research — providing the industry perspective on how device-generated data can improve treatment algorithms and patient-reported outcomes. They are a key industry partner for projects that need access to device ecosystems, patient data pipelines, and commercial healthcare insights.

What they specialise in

How they've shifted over time

Medtronic's H2020 involvement began in 2018 with a tight focus on diabetes — specifically hypoglycaemia data harmonization and CGM device outcomes (Hypo-RESOLVE). From 2019-2020, their focus broadened significantly toward general health outcomes infrastructure, obesity treatment algorithms, patient empowerment, and decentralized clinical trial methodologies. The shift signals a move from single-disease device data toward platform-level patient outcome measurement and treatment personalization across chronic conditions.

Medtronic is moving from disease-specific device contributions toward becoming an industry anchor for patient outcome data infrastructure and value-based healthcare models across multiple chronic conditions.

How they like to work

Medtronic exclusively participates as a consortium partner, never as coordinator — consistent with large industry players who contribute domain expertise and data assets rather than managing academic-heavy consortia. With 107 unique partners across 16 countries in just 4 projects, they operate in very large consortia (averaging ~27 partners per project). This makes them an accessible partner for big collaborative bids: they are experienced in multi-stakeholder research environments and comfortable contributing alongside universities, hospitals, and SMEs without needing to lead.

Across 4 projects, Medtronic has built connections with 107 unique partners spanning 16 countries — an unusually wide network for a small project count, reflecting participation in major pan-European health consortia. Their reach is thoroughly European with no apparent geographic concentration.

What sets them apart

As a global medical device giant, Medtronic brings something few academic or SME partners can: real-world device data at scale, commercial healthcare market insight, and an existing patient ecosystem spanning diabetes, obesity, and remote monitoring. For consortium builders, they are a credible industry validator — their participation signals commercial relevance and a pathway from research to market. They are particularly valuable in projects requiring interoperability between medical devices, clinical data systems, and patient-facing outcome tools.

Highlights from their portfolio

• H2O
  Health Outcomes Observatory builds a pan-European patient outcome data infrastructure with common data models — a foundational project for value-based healthcare across the continent.
• SOPHIA
  Develops personalized treatment algorithms for obesity using federated databases and shared value analysis — directly linking patient stratification to clinical decision-making.
• Trials@Home
  Center of Excellence for remote decentralized clinical trials — a model that became especially relevant post-COVID and could reshape how device companies run clinical studies.